{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD1&page=8", "query": { "intervention": "Anti-PD1", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 725, "total_pages": 73, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD1&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD1&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:31:20.691Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03711058", "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor", "Microsatellite Stable (MSS) Colon Cancer" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-01-17", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03711058" }, { "nct_id": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-08-08", "completion_date": "2031-12-23", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 29, "location_summary": "Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800015" }, { "nct_id": "NCT06411691", "title": "KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "KRAS Vaccine with Poly-ICLC adjuvant", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2024-11-04", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06411691" }, { "nct_id": "NCT02399371", "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Peritoneal Malignant Mesothelioma", "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Pleural Sarcomatoid Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-03-31", "completion_date": "2026-03-20", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399371" }, { "nct_id": "NCT05453799", "title": "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma" ], "interventions": [ { "name": "Vudalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2022-07-21", "completion_date": "2030-09-05", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453799" }, { "nct_id": "NCT03406715", "title": "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Lung Cancer", "Relapsed Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Dendritic Cell based p53 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-03-15", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406715" }, { "nct_id": "NCT04688658", "title": "Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Kirkwood", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-10-06", "completion_date": "2025-02-01", "has_results": true, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04688658" }, { "nct_id": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "RP3", "type": "BIOLOGICAL" }, { "name": "CCRT(concurrent chemoradiation therapy)", "type": "OTHER" }, { "name": "carboplatin and paclitaxel", "type": "OTHER" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-30", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743270" }, { "nct_id": "NCT03715946", "title": "Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck", "Oropharynx Squamous Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab Injection", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Robert L. Ferris, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-11-16", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Portland, Oregon • Pittsburgh, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03715946" }, { "nct_id": "NCT05789069", "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Melanoma", "Non Small Cell Lung Cancer", "Gastric Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "HFB200603", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiFiBiO Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2023-05-09", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-11-15T18:31:20.691Z", "location_count": 3, "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789069" } ] }